Hims & Hers Health, Inc.

52.02+0.26 (+0.5%)
Sep 12, 10:55:30 AM EDT · NYSE · HIMS · USD

Highlights

Hims & Hers runs a DTC telehealth platform selling recurring prescription care for hair, sexual, mental, and weight‑loss needs. The model scales with subscription economics. In Q2 2025 Hims posted $544.8 million revenue, up 73% YoY, 2.44 million subscribers, and $82.2 million adjusted EBITDA. Moat blends owned pharmacies, personalization data, and trust, lifting switching costs as customers bundle conditions into high‑retention plans. Timely catalysts include April 2025 Novo Nordisk collaboration offering Wegovy at $599 per month and FDA ending compounded semaglutide discretion May 22. The company is scaling profitably, reaffirming FY2025 revenue guidance of $2.3–$2.4 billion and reaching $74 monthly online revenue per subscriber in Q2. Risk is regulatory shifts and heavyweight rivals compressing GLP‑1 pricing or customer acquisition efficiency. hims.com hims.com, fda.gov hims.com

Upcoming Earnings

Report date
≈ Nov 3, 2025 (in 52 days)
EPS
0.26 (0.17 ~ 0.31)
Revenue
631.31M (592.70M ~ 685.04M)

Earnings History

No earnings history available

Key Stats

Market Cap
11.76B
P/E (TTM)
65.85
Basic EPS (TTM)
0.79
Dividend Yield
0%

About

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

CEO
Mr. Andrew Dudum
IPO
9/13/2019
Employees
1,637
Sector
Consumer Defensive
Industry
Household & Personal Products

Other Companies